Literature DB >> 9041265

New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine.

H Tilg1.   

Abstract

Interferon (IFN)-alpha is the most frequently used cytokine in the treatment of diseases of the gastrointestinal tract. This cytokine has emerged as an important regulator of growth and differentiation, affecting cellular communication and immunologic control. The efficacy of IFN-alpha has been shown in many different diseases of viral, malignant, angiogenic, allergic, inflammatory, and fibrotic origin. Cytokines are pleiotropic molecules with a wide variety of biological functions on various cells and tissues, and several different cytokines exert similar and overlapping functions on certain cells. Originally described as an antiviral substance, the role of IFN-alpha as an immunoregulatory molecule has long been ignored. Recent data suggest that IFN-alpha is a multifunctional immunomodulatory cytokine with profound effects on the cytokine cascade including several anti-inflammatory properties. These newly identified immunoregulatory and anti-inflammatory functions may be of importance in the treatment of diseases such as chronic viral hepatitis and help to explain some of the IFN mechanisms.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9041265     DOI: 10.1053/gast.1997.v112.pm9041265

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  56 in total

1.  Alpha interferon inhibits human herpesvirus 8 (HHV-8) reactivation in primary effusion lymphoma cells and reduces HHV-8 load in cultured peripheral blood mononuclear cells.

Authors:  P Monini; F Carlini; M Stürzl; P Rimessi; F Superti; M Franco; G Melucci-Vigo; A Cafaro; D Goletti; C Sgadari; S Butto'; P Leone; C Chiozzini; C Barresi; A Tinari; A Bonaccorsi; M R Capobianchi; M Giuliani; A di Carlo; M Andreoni; G Rezza; B Ensoli
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

2.  Current Views on Hepatitis C Virus Infection.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-02       Impact factor: 3.725

3.  Mechanism of action of ribavirin in the treatment of chronic hepatitis C.

Authors:  Helen S Te; Glenn Randall; Donald M Jensen
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-03

4.  Therapeutic implications of hepatitis C virus resistance to antiviral drugs.

Authors:  Jean-Michel Pawlotsky
Journal:  Therap Adv Gastroenterol       Date:  2009-07       Impact factor: 4.409

5.  Acute ulcerative colitis during successful interferon/ribavirin treatment for chronic hepatitis.

Authors:  R Sprenger; M Sagmeister; F Offner
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

6.  Clinical benefits and cost-effectiveness of 17-year treatment with low-dose interferon-alpha 2b in a patient with chronic hepatitis C: a case report.

Authors:  Takumi Kawaguchi; Shuji Sumie; Minoru Itou; Eitaro Taniguchi; Tsunetaka Matoba; Michio Sata
Journal:  Dig Dis Sci       Date:  2008-07-26       Impact factor: 3.199

7.  Interferon-alpha induces interleukin-18 binding protein in chronic hepatitis C patients.

Authors:  A Kaser; D Novick; M Rubinstein; B Siegmund; B Enrich; R O Koch; W Vogel; S H Kim; C A Dinarello; H Tilg
Journal:  Clin Exp Immunol       Date:  2002-08       Impact factor: 4.330

Review 8.  Interferon alpha treatment and thyroid dysfunction.

Authors:  Yaron Tomer; Jason T Blackard; Nagako Akeno
Journal:  Endocrinol Metab Clin North Am       Date:  2007-12       Impact factor: 4.741

9.  Despite increased plasma concentration, inflammation reduces potency of calcium channel antagonists due to lower binding to the rat heart.

Authors:  Saeed Sattari; William F Dryden; Lise A Eliot; Fakhreddin Jamali
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

10.  Interferon-induced protection against foot-and-mouth disease virus infection correlates with enhanced tissue-specific innate immune cell infiltration and interferon-stimulated gene expression.

Authors:  Fayna Diaz-San Segundo; Mauro P Moraes; Teresa de Los Santos; Camila C A Dias; Marvin J Grubman
Journal:  J Virol       Date:  2009-12-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.